Medical/Pharmaceuticals

Unlocking New Opportunities in Asia and the Greater Bay Area

SHANGHAI, July 16, 2025 /PRNewswire/ -- CPHI & PMEC China 2025 concluded in June with a record-breaking 109,056 attendees, fostering meaningful connections across the entire pharmaceutical supply chain. This remarkable success is a testament to the strong demand withinChina's thriving pharma indu...

2025-07-17 09:55 1450

Nature Medicine Published Phase 1 Results of Innovent Biologics' Anti-CLDN18.2 ADC (IBI343) in Patients with Advanced Gastric/Gastroesophageal Junction Adenocarcinoma

SAN FRANCISCO and SUZHOU, China, July 16, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune...

2025-07-17 08:00 2250

Flat Medical Honored at Premier, Inc.'s Annual Supplier Innovation Celebration

AUSTIN, Texas, July 16, 2025 /PRNewswire/ -- FlatTech LLC, doing business as Flat Medical today announced that it was honored during Premier, Inc.'s annual supplier Innovation Celebration at the 2025Breakthroughs Conference and Exhibition . The Innovation Ce...

2025-07-16 21:30 1726

SNB-101 Earns Government Backing as Promising Therapy for Small Cell Lung Cancer

SEONGNAM, South Korea, July 16, 2025 /PRNewswire/ -- In a strong endorsement of its cutting-edge drug delivery technology, SN BioScience announced that its anticancer candidate SNB-101 has been selected as a clinical-stage project under the 2025 Korea Drug Development Project, a government-initia...

2025-07-16 20:00 1890

WuXi Biologics Granted Highest Negligible-Risk ESG Rating from Morningstar Sustainalytics

* Best ESG rating tier of negligible-risk with a top 1% global ranking score * Industry and Regional ESG Top-Rated Company for five consecutive years * Leader in Green CRDMO to drive innovation for a healthier future SHANGHAI, July 16, 2025 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading ...

2025-07-16 18:00 1835

Senhwa Biosciences announces first patient dosed in NCI-sponsored pilot study of Pidnarulex (CX-5461) pharmacodynamics in patients with advanced solid tumors

TAIPEI and SAN DIEGO, July 15, 2025 /PRNewswire/ -- Senhwa Biosciences, Inc. (TPEx: 6492), a new drug development company focusing on first-in-class therapeutics for oncology, rare diseases, and infectious diseases, today announced that its new drug Pidnarulex (CX-5461) has been selected by the U...

2025-07-16 10:32 1821

Akeso Announces First Patient Enrolled in the Phase III Trial(AK112-312/HARMONi-GI6)of Ivonescimab for First-Line Treatment of Advanced Metastatic Colorectal Cancer

HONG KONG, July 15, 2025 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") is pleased to announce that the first patient has been successfully enrolled in the registration Phase III clinical trial (AK112-312/HARMONi-GI6) of ivonescimab in first-line treatment for advanced metastati...

2025-07-16 09:47 1997

Avio Health Launches AI Platform to Turn Disconnected Health Data into Preventive Intelligence

How Avio Health Is Rewiring Medicine for the Age of AI PALO ALTO, Calif. , July 15, 2025 /PRNewswire/ -- Today, Avio Health announced the launch of its proprietary clinical AI platform, which is designed to unify health data and support the shift toward preventative, personalized care. By integr...

2025-07-15 21:41 1438

Introducing the VARON VP-8G: A Smarter, Lighter Portable Oxygen Concentrator Built for Life on the Move

NEW YORK, July 15, 2025 /PRNewswire/ -- For those who need reliable oxygen support without compromising mobility,VARON proudly introduces the VP-8G portable oxygen concentrator

2025-07-15 20:25 1178

OSR Holdings Appoints Dr. Andreas Niethammer as Chief Medical Officer of Vaximm AG, an OSR Company

BASEL, Switzerland and SEOUL, South Korea, July 15, 2025 /PRNewswire/ -- OSR Holdings, Inc. (NASDAQ: OSRH), a global healthcare company dedicated to advancing healthcare outcomes and improving the quality of life for people and their families, today announced the appointment of Dr Andreas Nietham...

2025-07-15 19:30 1518

Baraya Extended Care Closes Series B Funding Round Bringing Total Capital Raised to USD 124 Million from TVM Capital Healthcare and a Syndicate of Prominent Investors

 TVM Capital Healthcare's oversubscribed fundraise for Baraya Extended Care addresses critical gaps in long-term care, supporting Saudi Arabia's Vision 2030 healthcare goals. DUBAI, UAE and  RIYADH, Saudi Arabia, July 15, 2025 /PRNewswire/ -- TVM Capital Healthcare announces the closing of a Ser...

2025-07-15 14:00 1616

Ascletis Completes Dosing of All Participants in Its U.S. Clinical Study Combining Adipose-Targeted, Once-Monthly Injectable Small Molecule THRβ Agonist, ASC47, and Semaglutide for the Treatment of Obesity

-          The combination study, conducted in the U.S., is designed to evaluate the safety, tolerability and preliminary efficacy at Day 29 of a single-dose of ultra-long-acting subcutaneously administered ASC47 (half-life up to 40 days) in combination with four doses of semaglutide (0.5 mg, onc...

2025-07-15 07:00 1973

Concord Healthcare Announces Completion of China's First Proton Therapy for Choroidal Malignant Melanoma

BEIJING, July 14, 2025 /PRNewswire/ -- Concord Healthcare Group Co., Ltd. ("Concord Healthcare"), a subsidiary of Concord Medical Services Holdings Limited (the "Company") (NYSE: CCM), which subsidiary is listed on the Main Board of The Stock Exchange of Hong Kong Limited (the "HKSE") under the s...

2025-07-15 04:05 1822

Illimis Therapeutics Closes 58 billion KRW ($42 million) Series B Financing to accelerate CNS and Immune Disease Drug Development via GAIA Platform

* Validates technological prowess of GAIA platform and intensifies global co-development effort, including the existing partnership with Lilly Catalyze360-ExploR&D * Funds to accelerate Alzheimer's and immune disease drug development, expanding GAIA-based pipeline SEOUL, South Korea, July 14,...

2025-07-14 15:38 1394

CARsgen Successfully Defends Its GPC3 CAR-T Patent at the EPO

SHANGHAI, July 13, 2025 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies, announces a favorable outcome in opposition proceedings before the European Patent Office (EPO) concerning its European patent EP34...

2025-07-14 08:00 1540

LG Debuts Next-Generation Precision Medical AI

Joint Development Underway: World-Class Precision Medical AI Platform with Vanderbilt University Medical Center SEOUL, South Korea, July 10, 2025 /PRNewswire/ -- LG AI Research announced on July 9 the official launch of 'EXAONE Path 2.0', its next-generation precision medical AI model. Followin...

2025-07-10 20:54 2289

Earendil Labs announces initiation of a phase 1 study of a half-life extended novel anti-TL1A antibody

MIDDLETOWN, Del., July 10, 2025 /PRNewswire/ -- Earendil Labs, an AI-empowered biotechnology company, announced that it has completed cohort 1 dosing in a phase 1 trial for a novel anti-TL1A antibody (HXN-1001). The phase 1 study is designed to evaluate the safety, tolerability, pharmacokinetics,...

2025-07-10 19:00 1646

Vita Therapeutics and I Peace announced a development program to generate iPS-derived differentiated cells for transplant therapy with an initial focus on FSHD (Facioscapulohumeral Muscular Dystrophy) using universal iPS cells

PALO ALTO, Calif., July 10, 2025 /PRNewswire/ -- Leading GMP cell CDMO I Peace, Inc. (https://ipeace.com/en/ ), specializing in induced pluripotent stem cells (iPSCs) and iPSC-derived cell therapies, announced that the company has agreed with Vita Therapeutics (Vita) to jo...

2025-07-10 18:00 2803

Zhimeng Biopharma's Next-Generation KCNQ2/3 Potassium Channel Opener Receives Clinical Trial Approval for ALS Phase 2/3 Study

SHANGHAI, July 9, 2025 /PRNewswire/ -- Shanghai Zhimeng Biopharma, Inc. ("Zhimeng Biopharma"), a clinical-stage biopharmaceutical company dedicated to innovative drug development for liver and central nervous system (CNS) diseases, today announced that its self-discovered next-generation KCNQ2/3 ...

2025-07-10 00:00 2254

GenScript Biotech Earns EcoVadis Silver Medal, Ranking in Top 15% Globally for Sustainability

PISCATAWAY, N.J., July 9, 2025 /PRNewswire/ -- GenScript Biotech Corporation (HK.1548), a leading global provider of life science research and manufacturing services, today announced that it has been awarded a Silver Medal by EcoVadis, a globally recognized business sustainability assessment plat...

2025-07-09 20:32 1932
1 ... 21222324252627 ... 248